Navigation Links
Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Date:2/5/2008

hich will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. The webcast replay will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide forward-looking guidance with respect to 2008.

The conference call dial-in numbers are 877-545-1489 for domestic callers and 719-325-4844 for international callers. The passcode for the call is 4452025. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 5:00 p.m. PT on February 5, 2008 to 11:59 p.m. PT on February 12, 2008. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 4452025.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) t
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
4. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
5. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
6. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. today ... financing. Led by Sears Capital Management and Biobrit LLC, ... Zakrzewski , the $1.5 million financing positions SiteOne to ... pain and to further develop its technology platform for ... In conjunction with the financing, Lowell ...
(Date:9/23/2014)... According to the new ... Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General & ... Forecasts to 2019", published by MarketsandMarkets, studies the global ... 2014 to 2019. The market is expected to ... 9.6% from 2014 to 2019. Browse ...
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... 2010 Diopsys, Inc. today announced the development of ... (SD-OCT) images to assist ophthalmologists and optometrists in diagnosing ... SD-OCT is an imaging technique used to ... Nerve Fiber Layer (RNFL) which can help them diagnose ...
... 20, 2010 A small Midwest college that is producing ... a $35 million grant from Lilly Endowment to launch a ... northern Indiana, has a Nobel Laureate in chemistry, the inventor ... and the first female commissioner of the U.S. Food and ...
Cached Medicine Technology:New Software for Improving the Analysis of OCT Images 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 2Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy 3
(Date:9/23/2014)... Given the nondiscretionary nature of ... and Vegetable Markets industry is generally stable; ... operators over the five years to 2014. Furthermore, ... demographic trends, including a focus on healthy eating ... fruit and vegetable consumption declined at an annualized ...
(Date:9/23/2014)... will present the results of their cancer research ... Madrid. , Joint Symposium: ESMO-ASCO: The Evolution ... 29, 11:00 AM - 12:30 PM, Room: Granada, ... Platforms support new forms of cancer clinical research? ... Proffered Paper session: Melanoma and other skin ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... million in supplemental funding to bolster the research of ... preclinical and clinical studies. , This investment encourages researchers ... for considering sex as a fundamental variable in research. ... can obscure key findings related to sex that could ... in greater awareness of the need to study both ...
(Date:9/23/2014)... cancer in their lifetime and 20 per cent of ... researchers from the University of Leicester has helped Avacta ... system for diagnosing lymphoma in dogs in the early ... cLBT (canine lymphoma blood test), this is the first ... status of a dog after undergoing chemotherapy. , ...
Breaking Medicine News(10 mins):Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:New hope for beloved family pets 2
... -- Primary school children cannot accurately estimate the speed of ... a new study. "This is not a matter of ... visual detection mechanisms," John Wann, lead researcher and a professor ... of London, said in a university news release. ...
... shows the NSAID Celebrex may help prevent some non-melanoma ... actinic keratoses lesions and are at high risk for ... of Alabama at Birmingham dermatologist and the study,s lead ... of celecoxib as a chemo-preventive agent for actinic keratoses. ...
... what might be one of the world,s first medicinal body ... have successfully implanted an experimental device in the throat of ... ability to swallow. The device, which could offer an effective ... controlled by pulling on a tiny metal pin that extends ...
... November 30, 2010The Council for Responsible Nutrition (CRN), the ... National Academy of Sciences Institute of Medicine,s (IOM) newly-released ... vitamin D "a modest step in the right ... and positive research that has consistently supported the need ...
... TUESDAY, Nov. 30 (HealthDay News) -- Acupuncture alters the ... finding that suggests the traditional Chinese treatment can effectively ... researchers used functional MRI scans to measure brain activity ... a device fitted to their left ankle. The researchers ...
... sleep apnea (OSA), a sleep disorder associated with obesity, ... arteries, according to a study presented today at the ... (RSNA). "Our study reveals that individuals with obstructive ... of atherosclerosis that puts them at risk for impaired ...
Cached Medicine News:Health News:Kids Can't Accurately Judge Speed of Approaching Cars: Study 2Health News:Celebrex may help prevent some non-melanoma skin cancers 2Health News:UC Davis surgeons test innovative device in patient with swallowing disorder 2Health News:UC Davis surgeons test innovative device in patient with swallowing disorder 3Health News:CRN reacts to Institute of Medicine DRI recommendations for vitamin D 2Health News:CRN reacts to Institute of Medicine DRI recommendations for vitamin D 3Health News:People with sleep apnea at higher risk for aggressive heart disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: